Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160175 | 0.95 | KDM4E (0.90) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL7158896 | 0.92 | KDM4E (0.90) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL7160381 | 0.91 | KDM4E (0.83) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL9434114 | 0.90 | KDM4E (0.81) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL7158385 | 0.89 | KDM4E (0.79) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL10860930 | 0.89 | KDM4E (0.79) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL10763917 | 0.88 | KDM4E (0.77) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL10669631 | 0.87 | KDM4E (0.77) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL11824836 | 0.87 | KDM4E (0.76) | KDM4EHSD17B10CASP1ALDH1A1CASP7 | |
| SCHEMBL10672390 | 0.87 | KDM4E (0.76) | KDM4EHSD17B10CASP1ALDH1A1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| EP-1109855-B1 | METHOD FOR PRODUCING THERMOSHAPED SUBSTRATES COATED WITH A SOL-GEL LACQUER | INST NEUE MAT GEMEIN GMBH (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | disclosed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | disclosed |
| EP-1109855-A1 | METHOD FOR PRODUCING THERMOSHAPED SUBSTRATES COATED WITH A SOL-GEL LACQUER | INSTITUT FÜR NEUE MATERIALIEN GEM. GMBH (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014149-A1 | METHOD FOR PRODUCING THERMOSHAPED SUBSTRATES COATED WITH A SOL-GEL LACQUER | INSTITUT FÜR NEUE MATERIALIEN GEM. GMBH (DE) | 2000-03-16 | — | — | WO | disclosed |
| US-4771057-A | TREATMENT OF ANGINA, ARRHYTHMIAS, CEREBRALVASCULAR DISEASE AND HYPERTENSION | UNIVERSITY OF ALBERTA (CA) | 1988-09-13 | — | — | US | disclosed |
| EP-0239186-A1 | Antihypertensive reduced pyridyl derivatives | The Governors of the University of Alberta (CA) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | KDM4E 1074/4885HSD17B10 3626/4885CASP1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.